




A. Neurotropic
Control strains




B. Patient C61




C. Patient C62




D. Patient C93




E. Patient C94




F. Patient C96



G. Patient C98




H. Patient C109




Approximate CD4 molecules/cell


I. Patient ES2




J. Patient ES3




K. Patient ES4





L. Patient ES7





M. Patient ES8




Relative infectivity (% max CD4/CCR5)







N. Patient ES9



O. Patient ES10



Approximate CD4 molecules/cell



Supplementary Figure 3 Full surface plots for chronic progressor (CP) and elite suppressor (ES) envelopes. (A-O) Surface plots are arranged by patient, including Yu-2 and SF-162 control strains, indicated in blue. CP envs are indicated in grayscale, and ES envs are indicated in red.